High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 67, Issue 3, 2012, Pages 431-438

  Van Der Veer, E ^a   Van Der Goot, W ^a   De Monchy, J G R ^a   Kluin Nelemans, H C ^a   Van Doormaal, J J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

fractures; mastocytosis; methylhistamine; osteoporosis; tryptase

Indexed keywords

HISTAMINE DERIVATIVE; METHYLHISTAMINE; METHYLIMIDAZOLEACETIC ACID; TRYPTASE; UNCLASSIFIED DRUG;

ADULT; AGE; ARTICLE; BONE DENSITY; FEMALE; FEMUR NECK; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; SEX DIFFERENCE; SYSTEMIC MASTOCYTOSIS; URINALYSIS; VERTEBRA FRACTURE;

EID: 84857191019     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2011.02780.x     Document Type: Article

References (36)

1. Akin C, Metcalfe DD,. Systemic mastocytosis. Annu Rev Med 2004; 55: 419-432.
2. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001; 25: 603-625.
3. Horny HP, Akin C, Metcalfe DD, et al. Mastocytosis (Mast cell disease). In:, Swerdlow, SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. editors. World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues, vol 2. Lyon, France: IARC Press, 2008: 54-63.
4. Escribano L, Úlvarez-Twose I, Sánchez-Muñoz L, Garcia-Montero A, Núñez R, Almeida J, et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish network on mastocytosis in a series of 145 patients. J Allergy Clin Immunol 2009; 124: 514-521.
5. Kors JW, Van Doormaal JJ, Breukelman H, Van Voorst Vader PC, De Monchy JG,. Long-term follow-up of indolent mastocytosis in adults. J Intern Med 1996; 239: 157-164.
6. Valent P, Akin C, Sperr WR, Horny HP, Arock M, Lechner K, et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 2003; 122: 695-717.
7. Travis WD, Li CY, Bergstralh EJ, Yam LT, Swee RGl,. Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine (Baltimore) 1988; 67: 345-368.
8. Barete S, Assous N, de Gennes C, Grandpeix C, Feger F, Palmerini F, et al. Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 2010; 69: 838-841.
9. Genant HK, Wu CY, van Kuijk C, Nevitt MC,. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993; 8: 1137-1148.
10. Kanis JA,. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 1994; 4: 368-381.
11. Donker ML, Van Doormaal JJ, Van Doormaal FF, Kluin PM, Van der Veer E, de Monchy J, et al. Biochemical markers predictive for bone marrow involvement in systemic mastocytosis. Haematologica 2008; 93: 120-135.
12. Granerus G, Lonnqvist B, Nystrand J, Roupe G,. Serum tryptase measured with B12 and G5 antibody-based immunoassays in mastocytosis patients and its relation to histamine turnover. Br J Dermatol 1998; 139: 858-861.
13. Keyzer JJ, Wolthers BG, Muskiet FA, Kauffman HF, Groen A,. Determination of N tau-methylhistamine in plasma and urine by isotope dilution mass fragmentography. Clin Chim Acta 1981; 113: 165-173.
14. Keyzer JJ, Wolthers BG, Breukelman H, Kauffman HF, de Monchy JG,. Determination of N tau-methylimidazoleacetic acid (a histamine metabolite) in urine by gas chromatography using nitrogen-phosphorus detection. Clin Chim Acta 1982; 121: 379-387.
15. Oosting E, Keyzer JJ, Wolthers BG, Scholtis RJ,. Age dependent normal values of histamine and histamine metabolites in human urine. Agents Actions 1988; 23: 307-10.
16. Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, et al. Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int 2000; 11: 669-674.
17. Van Staa TP, Dennison EM, Leufkens HGM, Cooper C,. Epidemiology of fractures in England and Wales. Bone 2001; 29: 517-522.
18. Ismail AA, Pye SR, Cockerill WC, Lunt M, Silman AJ, Reeve J, et al. Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int 2002; 13: 565-571.
19. Hedström EM, Svensson O, Bergström U, Michno P,. Epidemiology of fractures in children and adolescents. Acta Orthop 2010; 81: 148-153.
20. Cooper C, Dennison EM, Leufkens HG, Bishop N, van Staa TP,. Epidemiology of childhood fractures in Britain: a study using the general practice research database. J Bone Miner Res 2004; 19: 1976-1981.
21. Alvarez-Twose I, González de Olano D, Sánchez-Muñoz L, Matito A, Esteban-Lõpez MI, Vega A, et al. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol 2010; 25: 1269-1278.
22. Sambrook P, Cooper C,. Osteoporosis. Lancet 2006; 367: 2010-2018.
23. Bergström U, Björnstig U, Stenlund H, Jonsson H, Svensson O,. Fracture mechanisms and fracture pattern in men and women aged 50 years and older: a study of a 12-year population-based injury register, UmeÃ¥, Sweden. Osteoporos Int 2008; 19: 1267-1273.
24. Ebeling PR,. Osteoporosis in men. N Engl J Med 2008; 358: 1474-1482.
25. Harvey N, Dennisson E, Cooper C,. Epidemiology of osteoporotic fractures. In:, Rosen CJ, Compston JE, Lian JB, editors. Primer on the metabolic bone diseases and disorders of mineral metabolism, 7th edn. Washington DC: ASBMR, 2008: 198-203.
26. Chen W, Beck I, Schober W, Brockow K, Effner R, Buters JT, et al. Human mast cells express androgen receptors but treatment with testosterone exerts no influence on IgE-independent mast cell degranulation elicited by neuromuscular blocking agents. Exp Dermatol 2010; 19: 302-304.
27. Brumsen C, Papapoulos SE, Lentjes EG, Kluin PM, Hamdy NA,. A potential role for the mast cell in the pathogenesis of idiopathic osteoporosis in men. Bone 2002; 5: 556-561.
28. Chiapetta N, Gruber B,. The role of mast cells in osteoporosis. Semin Arthritis Rheum 2006; 36: 32-36.
29. Theoharides TC, Alysandratos KD, Angelidou A, Delivanis DA, Sismanopoulos N, Zhang B, et al. Mast cells and inflammation. Biochim Biophys Acta 2012; 1822: 21-33.
30. Theoharides TC, Boucher W, Spear K,. Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol 2002; 128: 344-350.
31. Brockow K, Akin C, Huber M, Metcalfe DD,. IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis. Clin Immunol 2005; 115: 216-223.
32. Kushnir-Sukhov NM, Brittain E, Reynolds JC, Akin C, Metcalfe DD,. Elevated tryptase levels are associated with greater bone density in a cohort of patients with mastocytosis. Int Arch Allergy Immunol 2006; 139: 265-270.
33. Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009; 113: 5727-5736.
34. Sánchez-Muñoz L, Alvarez-Twose I, García-Montero AC, Teodosio C, Jara-Acevedo M, Pedreira CE, et al. Evaluation of the WHO criteria for the classification of patients with mastocytosis. Mod Pathol 2011; 24: 1157-1168.
35. Sánchez-Muñoz L, Teodõsio C, Morgado JM, Escribano L,. Immunophenotypic characterization of bone marrow mast cells in mastocytosis and other mast cell disorders. Methods Cell Biol 2011; 103: 333-359.
36. Rossini M, Zanotti R, Bonadonna P, Artuso A, Caruso B, Schena D, et al. Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone 2011; 49: 880-885.